Sign Up
OverviewAPI
Several clinical-stage biopharmaceutical companies, including Zentalis Pharmaceuticals, Taysha Gene Therapies, Kura Oncology, and ORIC Pharmaceuticals, have granted equity inducements to new employees to support their work in developing treatments for cancer and genetic diseases. These inducements involve stock options with varying exercise prices and vesting schedules, highlighting the companies' commitment to attracting top talent and advancing innovative therapies in the healthcare industry.

Ask a question